Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MirtaRett: Repurposing mirtazapine in Rett syndrome
2024-515411-21-00Phase 2Authorised
- Sponsor
- University of Trieste
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mirtazapine in Rett syndrome (RTT), sponsored by University of Trieste. Primary endpoint: Change in Motor-Behavior Assessment Scale (MBAS). Planned start Feb 2025; status: authorised.
02
Drugs
mirtazapine
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on 2024-515411-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515411-21-00.